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( 597) polymorphisms and IL-6 levels with hepatitis B virus
related HCC risk in Indian population.
Methods: Five groups of subjects were enrolled viz. control
(n = 100), HBV-carriers (n = 60), chronic active HBV (n = 60),
HBV-cirrhotic (n = 60) and HBV-related HCC (n = 53). PCR-
RFLP was performed to study various polymorphic forms of
IL-6 and levels in PBMCs were estimated by ELISA. Genotype
distributions were compared using chi square analysis and
the odds ratios (ORs) and 95%CI were calculated to express
the relative risk.
Results: In IL-6 ( 572), the GC genotype, was in negative
association (p < 0.001) with HCC, among controls, while it
was a signiﬁcant risk factor (p < 0.001) for the same, among
HBV-carriers. In contrast, the CC genotype was a risk factor
(p < 0.001) for progression the disease to cirrhosis among
controls and HBV-carriers (OR: 3.2 and 4.0 respectively).
In case of IL-6( 597), GA genotype signiﬁcantly increased
(p < 0.001) HCC risk, both among controls and HBV-carriers.
The IL-6 levels were found to be signiﬁcantly lower in all the
diseased groups, with reference to controls. However, levels
were signiﬁcantly higher in cirrhotic group when compared
with the carrier and active hepatitis group. Moreover, in
both IL-6( 572) and ( 597) heterozygotes were found to
have lower IL-6 levels as compared to those having wild
genotypes.
Conclusions: Polymorphic forms of IL-6 and basal IL-6
levels share a strong association with HBV-HCC risk in
Indian population and thus should be further evaluated
as candidate genes to determine individual susceptibility
for the same.
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Objectives: Evaluate the efﬁcacy of Tiaoganjanpihexue (a
traditional Chinease medicine term) CHM-prescription for
treating a 31-year-old female HBeAg(+) chronic hepatitis B
Chinese patient with suboptimal response to Adefovir
Dipivoxil (AD) for 63 weeks switch to AD + lamivudine (LVD)
for 18 weeks, and to AD for 45 weeks, and to Telbivudine
(TEB) for 24 weeks. Modeling the dynamics of the anti-HBV
infection treatments.
Methods: During 2007 2010, the patient was treated
by AD, AD+LVD, AD and TEB continuously. Her baseline
characteristics were HBV DNA = 3.48×107 cps/ml, ALT
= 103.2 I/U, HBeAg = 1.400 S/CO, Anti-HBe = 0.213S/CO
and those at week 150 were HBV DNA <1000 cps/ml,
ALT <14 I/U (over 100 weeks), HBeAg = 3.840S/CO, Anti-
HBe = 1.061S/CO. After 16 weeks’ stopping treatment, her
HBV DNA was returned to 6.8×103 and other characteristics
were almost the same as those at week 150. Using the CHM
Tiaoganjanpihexue (consisting of 21 ingredients) treated the
patient, two times daily and decoction after meals.
Results: After 4 weeks’ treatment her HBeAg and anti-
HBe reduced to 0.850S/CO and 0.528S/CO. Following
21 weeks’ addtional treatments, her HBeAg had been kept
seroconversion and HBV DNA reduced to 1.40×103 cps/ml.
During the 25 week’s Tiaoganjanpihexue therapy, her mean
ALT = 19.03 I/U. A mathematical new model is introduced to
model the dynamics of the anti-HBV infection treatment.
The simulated curve is in good agreement with the clinic
tested patient’s HBV DNA.
Conclusions: The CHM Tiaoganjanpihexue has a speciﬁc
function that is able to activate patient’s immune function
to suppress HBV directly but not injure the patient’s
hepatocytes.
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Objective: To detecte HBV subtypes, mutation of core
promoter and precore/core and clinical features among
Xinjiang Uygur patients with chronic HBV infection.
Methods: PCR-RFLP was used to detect the subtypes, core
promoter and precore/core of HBV in 109 Uygur patients
with chronic HBV, and analyses of the relationship between
mutation and clinical features.
Results: In 109 Uygur patients with chronic HBV group, there
were 9 cases with HBV genotype B infection who were HBV
Ba subtype, 50 cases with HBV genotype C and 27 cases
with C1 subtype i, 23 cases with C2 subtype, 32 cases
with C/D recombinant i, 18 cases with HBV genotype D
infection. According to the progress of the HBV infection,
G1896A mutation in HBV precore or core region had no
signiﬁcant difference in chronic hepatitis B and cirrhosis,
but A1762T/G1764A mutation in the HBV subtype C1 and C2
and i Ba have signiﬁcantly increased in cirrhosis.we fund that
A1762T/G1764A mutation in HBV C/D recombinant infection
is low.
Conclusion: Uygur patients with CHB have more HBV C/D
recombinant, and C1 subtype infection. A1762T/G1764A
mutation in the HBV subtype C1 and C2 subtypes have
signiﬁcantly increased.
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Objective: Previous studies showed that HBV genotype
correlated with HBV transmission, clinical disease spectra,
progression, prognosis, antiviral effect, etc. This study
is aimed to evaluate the clinical signiﬁcance of HBV
genotype.
Methods: HBV genotypes were analyzed in 280 patients
infected with hepatitis B virus. Liver function, HBV markers
including PreS1, HBV DNA levels and T cell subsets of these
patients were also measured.
Results: HBV genotyping had a geographical distribution.
Genotype C was mainly prevalent in patients from north
china while Genotype B from south china. In the progression
of asymptomatic carrier or acute hepatitis to chronic
hepatitis, liver cirrhosis and liver cancer, genotype C
increased while genotype B decreased. Genotype C and
genotype BC showed lower levels in prealbum (Pre-A)
and album (ALB) and lower ratio of album to globulin
(A/G) than genotype B (P= 0.02, P= 0.03, P= 0.01 and
P= 0.005, P= 0.001, P< 0.001, respectively), but showed
higher levels in globulin (GLO) than genotype B (P< 0.001
and P= 0.01, respectively). Genotype C showed lower levels
in cholinesterase (CHE) than genotype B (P= 0.007). There
